JAMA Dermatology

<jats:p>This case series examines the effectiveness of dupilumab as a steroid-sparing therapy among patients with antibody-drug conjugate–related cutaneous toxicities.</jats:p>

A review of the clinical efficacy of FDA-approved antibody–drug conjugates in human cancers.

Mol Cancer

Dermatologic toxicities of antibody-drug conjugates.

J Am Acad Dermatol

Management of immune-related cutaneous adverse events with dupilumab.

J Immunother Cancer

Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.

Int J Clin Oncol

Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells.

Oncoimmunology

Types of necroinflammation, the effect of cell death modalities on sterile inflammation.

Cell Death Dis

This case series examines the effectiveness of dupilumab as a steroid-sparing therapy among patients with antibody-drug conjugate–related cutaneous toxicities.

Use of Dupilumab to Manage Antibody-Drug Conjugate-Induced Cutaneous Toxicities.

Use of Dupilumab to Manage Antibody-Drug Conjugate–Induced Cutaneous Toxicities

Use of Dupilumab to Manage Antibody-Drug Conjugate–Induced Cutaneous Toxicities

Clinical Summary

What was studied

Study limitations

Related Questions